Skip to contentA
Axim Biotechnologies, Inc.
A
AXIMAxim Biotechnologies, Inc. Q1 2018 · 10-Q
Revenue$14.25K$14.25K−23.5% vs Q1 2017 Net Income-$2.76M-$2.76MN/M vs Q1 2017 EPS Diluted-$0.05-$0.05N/M vs Q1 2017 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Axim Biotechnologies, Inc. · CIK 1514946 · Engraved from SEC EDGAR
Operating Cash Flow-$1,163,362N/M Margins · derivedGross margin88.0%+197.1 pt vs Q1 2017
Operating margin-14291.1%−11733.0 pt vs Q1 2017
Net margin-19395.6%−16580.6 pt vs Q1 2017
ended Mar 31, 2018 · filed May 15, 2018 · 45 d after period end